Literature DB >> 211637

Small cell bronchogenic carcinoma: a distinct clinicopathologic entity.

M H Cohen, M J Matthews.   

Abstract

Since small cell carcinoma is a treatable disease, with surgery being beneficial in a few cases and with chemotherapy, radiotherapy, and immunotherapy contributing to prolonged survival in patients with inoperable disease, it is essential that the clinical and pathologic features of small cell carcinoma be quickly recognized in a newly presenting patient so that appropriate therapy may be offered.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 211637

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  19 in total

1.  Rapid tumor doubling in the CNS.

Authors:  Jesica A Christensen; Linda Bressler; Kiran Bath; Suhda Chichili; J Lee Villano
Journal:  J Neurooncol       Date:  2007-11-27       Impact factor: 4.130

2.  Constitutional abnormality of nuclear membrane proteins in small cell lung carcinoma.

Authors:  Jieying Wang; Tetsuo Kondo; Tadao Nakazawa; Naoki Oishi; Kunio Mochizuki; Ryohei Katoh
Journal:  Virchows Arch       Date:  2019-06-15       Impact factor: 4.064

3.  Expression of the C-terminal peptide of human pro-bombesin in 361 lung endocrine tumours, a reliable marker and possible prognostic indicator for small cell carcinoma.

Authors:  Q A Hamid; B J Addis; D R Springall; N B Ibrahim; M A Ghatei; S R Bloom; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 4.  Role of radiation therapy in small cell lung cancer: a bio-clinico-pathological review and perspective.

Authors:  S Vijayakumar; K Shepard; F Thomas; J Weick; T Rice; A Mehta
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

5.  Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.

Authors:  M Mabry; J A Speak; J D Griffin; R A Stahel; S D Bernal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

6.  Gastric small cell carcinoma with marked response to neoadjuvant chemotherapy.

Authors:  Yasuhiro Nakamura; Setsuya Otani; Michiro Otaka; Tomoyuki Shimada; Satsuki Takahashi; Masahiro Saito; Tohru Takahashi; Masahumi Komatsu; Toshie Suzuki; Shunji Okubo; Masato Hayashi; Hironobu Sasano
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

7.  New approach to assessing lung tumours in man.

Authors:  K C Gatter; M S Dunnill; J Gerdes; H Stein; D Y Mason
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

Review 8.  Small cell anaplastic carcinoma of the lung. A review of growth characteristics and implications for chemotherapy.

Authors:  B A Brigham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.

Authors:  J Aisner; M Whitacre; D A VanEcho; M Wesley; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 10.  Therapeutic procedure in small cell lung cancer.

Authors:  Anastasios Kallianos; Aggeliki Rapti; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Qiang Li; Haidong Huang; Bojan Zaric; Branislav Perin; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.